Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors

TOP - September 2020 Vol 13, No 5 - Emerging Therapies

A novel intratumoral chemotherapy agent delivered by direct injection permits the dispersion of cytotoxic drugs into cancer cells to eradicate tumors. Data from a phase 1/2 trial of intratumoral INT230-6, alone and in combination with pembrolizumab (Keytruda), in patients with advanced solid tumors was presented at the ASCO 2020 virtual annual meeting by Jacob Stephen Thomas, MD, Assistant Professor of Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles.

“INT230-6 is composed of cisplatin, vinblastine, and an amphiphilic cell-­penetration excipient small molecule that improves intracellular transport and tissue dispersion by passive diffusion,” said Dr Thomas. “When cytotoxic agents alone are administered, the majority of the drug leaks out of the tumor. In contrast, the novel INT230-6 formulation enables cytotoxic drugs to disperse and stay within the tumor, which has resulted in prolonged disease control in several patients with different tumor types,” said Dr Thomas.

“When INT230-6 is injected, little to no drug leaks out of the tumor, and on bisection, the drug disperses equally throughout the tumor,” said Dr Thomas. “Histologically, we see significant cytotoxic effects with this agent, and preclinical experiments have shown strong synergy with a PD-1 antibody.”

Furthermore, “The treatment has been well tolerated both as monotherapy and in combination with pembrolizumab,” he added.

Dr Thomas and colleagues enrolled patients with solid tumors that had progressed with standard treatment. A significant proportion of patients had received previous treatment with platinum, as well as with PD-1 inhibitor. The median number of previous therapies was 3, with a maximum of 10 therapies.

The dose of INT230-6 was set by tumor volume, and dose escalation was done by increasing the number of tumors injected, loading per tumor, and total dose. Pembrolizumab was also combined with INT230-6 in a separate arm of the study. Patients were monitored for safety weekly while receiving INT230-6, and blood and tumors were assessed for pharmacokinetics and pharmacodynamics.

At the time of the data cutoff, 59 patients with highly refractory disease had been recruited, including 52 in the monotherapy cohort and 7 in the combination arm with pembrolizumab. A total of 13 patients with highly refractory tumors have had disease stabilization for >6 months, and 10 patients had some size reduction of ≥1 noninjected lesions in the lymph nodes, liver, lung, perineum, and retroperitoneal areas.

“There’s evidence of preliminary efficacy with INT230-6. We see prolonged disease control in several patients with different tumor types,” Dr Thomas said.

Pharmacokinetics have been favorable. Intratumor dosing of INT230-6 with an equivalent of 10 mg of vinblastine led to approximately 5% systemic absorption when compared with a historic control.

Adverse Events

When given as monotherapy, INT230-6 had relatively few grade 3 adverse events and no grade 4 adverse events.

“The most common treatment-related adverse event was localized pain at the injection site, which is typically transient and managed well with supportive care and pain medications,” said Dr Thomas.

INT230-6 in combination with pembrolizumab was similarly well-tolerated. The most common adverse event was localized pain, and no dose-limiting toxicities have been observed to date.

In patients responding to injection of INT230-6, investigators observed systemic increases of CD4-positive and CD8-positive T-cells compared with nonresponding patients, suggesting systemic immune-cell activation.

The study continues to enroll patients in the INT230-6 monotherapy cohort, as well as in the cohort of INT230-6 in combination with pembrolizumab. In addition, a cohort receiving INT230-6 in combination with ipilimumab (Yervoy) is planned to open soon, said Dr Thomas.

Related Items
NCCN Risk Classification Suboptimal for Some African-American Men with Prostate Cancer
Charlie Dawson
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Prostate Cancer
Targeted Radiotherapy Prolongs Survival in Patients with Advanced Prostate Cancer
Charlie Dawson
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Prostate Cancer
Survey of Oncologists Reveals Ongoing Misconceptions and Concerns Regarding Biosimilars
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ASCO Quality Care Symposium
Analysis of Healthcare Claims Shows Encouraging Trend in the Use of Trastuzumab Biosimilars
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ASCO Quality Care Symposium
Pharmacist-Driven Intervention Leads to Significant Increase in Biosimilar Adoption
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ASCO Quality Care Symposium
Multidisciplinary Team Approach Leads to Rapid Biosimilar Adoption in Community Oncology Practice
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Best Practices
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
The Impact of Racial Disparities in Cancer Care
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Disparities in Oncology
New Opportunities in Clinical Trials and Drug Development After COVID-19
Charlie Dawson
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in HOPA Highlights
Dismantling Structural Racism in Oncology Pharmacy
Charlie Dawson
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in HOPA Highlights
Last modified: July 22, 2021